Sponsored by Sanofi Aventis
A Phase II multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer’s Disease on stable donepezil therapy.
Sponsored by Pfizer (formerly known as Wyeth)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-Carriers
Please contact Juanita M Smith, Senior Research Coordinator at 732-657-6100 or fill out the form below with any questions regarding the above.
